US 9475871
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
granted A61KA61K38/179A61K39/3955
Quick answer
US patent 9475871 (Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins) held by Five Prime Therapeutics, Inc. expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Five Prime Therapeutics, Inc.
- Grant date
- Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K38/179, A61K39/3955, A61K45/06, A61P